Baird Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $90

Benzinga · 1d ago
Baird analyst Brian Skorney maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $97 to $90.